Cargando…
Relapse of membranous nephropathy with cancer immunotherapy
Advances in monoclonal antibody technology have enabled the application of engineered antibodies to interfere with specific immune pathways. Checkpoint inhibitors have shown promising results in treating certain cancers by employing patients’ own immune systems to attack cancer cells. Checkpoint inh...
Autor principal: | Kim, Youngho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857825/ https://www.ncbi.nlm.nih.gov/pubmed/33564446 http://dx.doi.org/10.1093/ckj/sfz074 |
Ejemplares similares
-
Relapsing minimal change disease superimposed on late-onset p.N215S Fabry nephropathy
por: Salerno, Fabio R, et al.
Publicado: (2021) -
Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab
por: Ginthör, Noemi E, et al.
Publicado: (2021) -
Backtracking cryptic recurrence of esophageal cancer from membranous nephropathy: the detection of glomerular NELL-1 and IgG4
por: Zhou, Shuai, et al.
Publicado: (2022) -
Idarucizumab for the treatment of dabigatran-related nephropathy
por: Alsamarrai, Ammar, et al.
Publicado: (2020) -
Myeloid bodies caused by COQ2 mutation: a case of concurrent COQ2 nephropathy and IgA nephropathy
por: Ni, Hai-Feng, et al.
Publicado: (2021)